Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BiDil cost-effectiveness

Executive Summary

Nitromed's BiDil contributed to reduced heart failure-related and overall healthcare costs due to a reduction in the number and length of heart failure-related hospitalizations, according to a pharmacoeconomic analysis of the African American Heart Failure Trial (A-HEFT) published in Circulation Dec. 13. The analysis, conducted by Derek Angus, University of Pittsburgh, et al., found that including an average daily drug cost of $6.38, use of isosorbide dinitrate/hydralazine reduced costs and improved outcomes during the 12.8 month trial duration. Assuming no additional benefits beyond the trial, the analysis predicted that cost-effectiveness of the therapy using heart failure-related costs to be $16,600/life-year at two years after enrollment, $37,100/life-year at five years and $41,800/life-year over a lifetime...

You may also be interested in...



GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation

Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.

Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research

Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.

FDA Guides On Virtual Inspections During COVID-19

Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.

Topics

UsernamePublicRestriction

Register

PS046668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel